Stop GLP-1s and the Weight Comes Back? What the WHO Review Actually Says

Disclaimer — This article is general medical information and does not replace diagnosis or prescription. Any decision to start, stop, or switch GLP-1 drugs must be made with a healthcare provider.

1. What to notice

What happens when you start GLP-1 drugs like Wegovy, Ozempic, or Zepbound — and then stop? Three recent WHO-commissioned reviews plus follow-up research now provide an answer. One-line summary: "Stop them and you'll regain quickly, but there are multiple paths."

*Photo by Kristine Wook on Unsplash*

2. What the WHO review found on efficacy

According to ScienceDaily's coverage, three WHO-commissioned reviews synthesized the data on GLP-1 efficacy.

Drug	Average weight loss (12–18 months)
Tirzepatide (Mounjaro/Zepbound, weekly)	~16%
Semaglutide (Ozempic/Wegovy)	~15%
Liraglutide	~8%

That's a meaningful range in obesity treatment. The catch: those numbers reflect continuous use.

3. What happens after stopping?

A follow-up ScienceDaily report and NPR's analysis point in the same direction.

"Weight regain after stopping GLP-1s tends to be faster than after weight loss achieved through diet and exercise alone."

— WHO review summary

Key data points:

• One-year persistence: fewer than 25% of patients are still on the drug a year after starting
• That is, 3 out of 4 stop within a year
• Reasons vary: side effects, cost, doubts about efficacy, supply shortages

4. But not everyone regains

A March ScienceDaily report flagged an interesting follow-up. In a ~8,000-person real-world cohort:

• Common patterns among those who stopped but maintained:

- Restarting (same drug or another GLP-1) - Switching to another GLP-1 (e.g., Wegovy → Zepbound) - Stepping up diet and exercise

• "Stopping equals yo-yo" is not automatic. But stopping without a plan tends to lead to fast regain.

*Photo by Melany @ tuinfosalud.com on Unsplash*

5. So how should they be used?

Treating GLP-1s as a short-term diet tool is a risky framing. The overall WHO review tone:

• Treat as long-term therapy — like managing hypertension or diabetes
• Routine monitoring with a physician to track side effects
• Pair with exercise and diet — and plan for the day you stop
• Watch for muscle loss — protein intake and strength training matter

6. Why this matters for Korea

The Wegovy launch in Korea is covered in a separate post. GLP-1 prescriptions are rising domestically, but the drugs are not reimbursed, so monthly out-of-pocket costs of roughly KRW 800,000–950,000 (~$600–700) are typical. Going in knowing that "stopping leads to fast regain" matters as much as the decision to start.

*Photo by Israt Yasmin Piya on Unsplash*

7. TL;DR

• WHO-commissioned reviews: tirzepatide ~16%, semaglutide ~15% weight loss over 12–18 months
• Post-discontinuation regain is faster than after diet-and-exercise loss
• One-year GLP-1 persistence is under 25%
• But restart, switch, and lifestyle reinforcement can preserve results (8,000-person cohort)
• Frame this as chronic disease management, not a short-term diet aid

Building a plan for "what happens when I stop" matters more than the decision to start.

Check out more from our health category, or the #GLP-1 and #diet tags. Our piece on Survodutide's Phase 3 trial is a useful companion read.

8. Sources

Sources: ScienceDaily — WHO review, ScienceDaily — persistence, ScienceDaily — restart study, NPR